Life Sciences Innovation

The Fleming Centre

Opening in 2028 at St. Mary's Hospital in northwest London, The Fleming Centre will stand at the forefront of the battle against AMR. Through its innovative and collaborative approach, it seeks to raise awareness, drive behaviour change, and develop evidence-based solutions to combat the growing threat of drug-resistant microbes. 

By engaging with the public, policymakers and scientific experts, The Fleming Centre aims to pave the way for sustained efforts to mitigate the impact of AMR. The centre is also a key part of Imperial College Healthcare NHS Trust's Paddington Life Sciences development, which aims to create a thriving ecosystem for life sciences research and innovation.

Securing the next century of health 

The UK government's recent investment in manufacturing, research and The Fleming Centre are prudent steps towards tackling this challenge and will begin this movement for change. The centre's transformative new approach to solving a global issue can be shared and adapted to local contexts. 

To ensure that new treatments reach patients, it is important to support the entire process from drug discovery to scaled manufacturing. To provide effective and efficient healthcare solutions to those in need, a multi-faceted approach that addresses appropriate antibiotic prescribing, infection control, public education, and international coordination on resistance will prove most effective. 

2028 marks the 100th anniversary of the discovery of penicillin and we should reflect on how far medicine has come thanks to visionary discoveries like Fleming's. This centenary must also spark renewed efforts to sustain antibiotic innovation. With collective commitment, we can future-proof antimicrobial defences for the next 100 years of healthcare.